ELENA TOVAR AMBEL

Dr. ELENA TOVAR AMBEL

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MMMaría Martínez-García
María Martínez-García
GDGuillermo Velasco Díez
Guillermo Velasco Díez
EPEstela Pineda
Estela Pineda
MGMiguel Juan Gil Gil
Miguel Juan Gil Gil
FAFrancesc Alameda
Francesc Alameda
Juan-Manuel Sepúlveda SánchezJuan-Manuel Sepúlveda Sánchez
Juan-Manuel Sepúlveda Sánchez
Background: MET-signaling and midkine (ALK ligand) promote glioma cell maintenance and resistance against anticancer therapies. ALK and c-MET inhibition with crizotinib have a preclinical therapeutic rationale to be tested in newly diagnosed GBM. Methods: Eligible patients received crizotinib with standard radiotherapy (RT)/temozolomide (TMZ) followed by maintenance with crizotinib. The primary objective was to determine the recommended phase 2 dose (RP2D) in a 3 + 3 dose escalation (DE) strategy and safety evaluation in the expansion cohort (EC). Secondary objectives included progression-free (PFS) and overall survival (OS) and exploratory biomarker analysis. Results: The study enrolled 38 patients. The median age was 52 years (33–76), 44% were male, 44% were MGMT methylated, and three patients had IDH1/2 mutation. In DE, DLTs were reported in 1/6 in the second cohort (250 mg/QD), declaring 250 mg/QD of crizotinib as the RP2D for the EC. In the EC, 9/25 patients (32%) presented grade ≥3 adverse events. The median follow up was 18.7 months (m) and the median PFS was 10.7 m (95% CI, 7.7–13.8), with a 6 m PFS and 12 m PFS of 71.5% and 38.8%, respectively. At the time of this analysis, 1 died without progression and 24 had progressed. The median OS was 22.6 m (95% CI, 14.1–31.1) with a 24 m OS of 44.5%. Molecular biomarkers showed no correlation with efficacy. Conclusions: The addition of crizotinib to standard RT and TMZ for newly diagnosed GBM was safe and the efficacy was encouraging, warranting prospective validation in an adequately powered, randomized controlled study.

Verified
Journal Article
Open access
PDF file
MKMagdalena Kusaczuk
Magdalena Kusaczuk
EAELENA TOVAR AMBEL
ELENA TOVAR AMBEL
PMPaola Martín-Cabrera
Paola Martín-Cabrera
MLMar Lorente
Mar Lorente
NSNélida Salvador-Tormo
Nélida Salvador-Tormo
MNMONIKA NAUMOWICZ
MONIKA NAUMOWICZ
Despite the increasing understanding of the pathogenesis of glioblastoma (GBM), treatment options for this tumor remain limited. Recently, the therapeutic potential of natural compounds has attracted great interest. Thus, dietary flavonoids quercetin (QCT) and kaempferol (KMF) were investigated as potential cytostatic agents in GBM. Moreover, the physicochemical properties of QCT and KMF, determining their bioavailability and therapeutic efficiency, were evaluated. We proved that both polyphenols significantly reduced the viability of GBM cells. We also demonstrated that both QCT and KMF evoked the cytotoxic effect in T98G cells via induction of apoptotic cell death as shown by increased activity of caspase 3/7 and caspase 9 together with an overexpression of the cleaved form of PARP. Apoptosis was additionally accompanied by the activation of stress responses in QCT- and KMF-treated cells. Both polyphenols caused oxidative stress and endoplasmic reticulum (ER) stress, as demonstrated by the increased generation of reactive oxygen species (ROS), deregulated expressions of superoxide dismutases (SOD2 and Sod1 on protein and transcriptomic levels, respectively), as well as an overexpression of ERO1α, GRP78, p-JNK, and an up-regulation of Chop, Atf4 and Atf6α genes. The antitumor effect of QCT and KMF was also confirmed in vivo, showing reduced growth of tumor xenografts in the chick chorioallantoic membrane (CAM) experiment. Moreover, electrophoretic light scattering (ELS) was used to measure the zeta potential of cell membranes upon exposition to QCT and KMF. Additionally, on the basis of existing physicochemical data, the drug-likeness score of QCT and KMF was evaluated. Analyses showed that both compounds accomplish Lipinski’s Rule of 5, and they both fit into the criteria of good central nervous system (CNS) drugs. Altogether, our data support the idea that QCT and KMF might be plausible candidates for evaluation as therapeutic agents in preclinical models of glioblastoma.

10 April 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
BSBerta Segura-Collar
Berta Segura-Collar
BCBlanca Cómitre-Mariano
Blanca Cómitre-Mariano
DLDenisse Alcivar López
Denisse Alcivar López
LMLucia Modejar-Ruescas
Lucia Modejar-Ruescas
MCMarta Caamaño-Moreno
Marta Caamaño-Moreno
Juan-Manuel Sepúlveda SánchezJuan-Manuel Sepúlveda Sánchez
Juan-Manuel Sepúlveda Sánchez
The lack of response of glioblastoma (GBM) to immunotherapy is closely related to the limited number of T cells in the tumor microenvironment. However, it is still not known why GBM is characterized by an immune-cold tumor microenvironment with reduced CD8+ T-cell infiltration when there is substantial myeloid cell infiltration and a substantial alteration of the blood-brain barrier. The aim of this study was to identify regulators of low CD8+ T-cell infiltration in GBM. Using transcriptomic screening, we found that tribbles homolog 2 (TRIB2) is a regulator of the immune-cold microenvironment characteristic of GBM. Further analysis of a cohort of 114 brain tumors with IHC, RNA sequencing, and qRT-PCR showed that TRIB2 inhibited the transcription of genes involved in antigen presentation by the tumor cells and those involved in T-cell recruitment by modulating the expression of methylation regulators, in particular DNA methyltransferase 1. Further, we observed 75% survival after TRIB2 inhibition in murine glioma models and showed transcriptomic reprogramming by decitabine of genes involved in the processes described above. In our patient-derived tumor fragments assay, we observed a consistent, generalized response to decitabine, suggesting that DNA methyltransferase 1 inhibition (DNMT1) could be a promising therapeutic strategy for GBM.

15 August 2026 in Neuroscience
Verified
Journal Article
Open access
LGLaura Gálvez-Melero
Laura Gálvez-Melero
EMEdurne Mugica-Urruzola
Edurne Mugica-Urruzola
EAELENA TOVAR AMBEL
ELENA TOVAR AMBEL
GDGuillermo Velasco Díez
Guillermo Velasco Díez
MGM. Julia García-Fuster
M. Julia García-Fuster


2 July 2025
Verified
Other
Open access
PDF file
BSBerta Segura-Collar
Berta Segura-Collar
BCBlanca Cómitre-Mariano
Blanca Cómitre-Mariano
DLDenisse Alcivar López
Denisse Alcivar López
LMLucia Modejar-Ruescas
Lucia Modejar-Ruescas
MCMarta Caamaño-Moreno
Marta Caamaño-Moreno
Juan-Manuel Sepúlveda SánchezJuan-Manuel Sepúlveda Sánchez
Juan-Manuel Sepúlveda Sánchez
Supplementary figure S2. TRIB2 expression is associated with proliferation processes and vascular cells in GBM.